论文部分内容阅读
目的探讨HER-2阳性乳腺癌患者应用曲妥珠单抗治疗的安全性。方法 45例HER-2阳性乳腺癌患者接受3周1次的曲妥珠单抗治疗,首次以负荷剂量8 mg/kg给药,然后每3周给予6mg/kg静脉滴注,观察其毒副反应,特别是对心脏功能的影响。结果 45例中接受治疗>1年为4例(8.9%),6~12个月为17例(37.8%),<6个月为24例(53.3%)。有2例在第1次用药时出现寒战和发热;6例患者治疗后左心射血分数下降,其中2例下降超过10%;19例治疗过程中出现轻度ST-T波改变,但未出现心力衰竭。结论曲妥珠单抗对HER-2阳性国人乳腺癌患者心脏功能有一定影响,应在治疗中注意监测观察,但总体安全性良好。
Objective To investigate the safety of trastuzumab in patients with HER-2 positive breast cancer. Methods Forty-five patients with HER-2 positive breast cancer received trastuzumab once a week for 3 weeks. The first dose was given at a loading dose of 8 mg / kg, and then every 6 weeks after 6 mg / kg intravenous drip. The toxicity Response, especially on cardiac function. Results 45 of the 45 patients were treated for> 1 year in 4 patients (8.9%), 6 to 12 months in 17 patients (37.8%) and <6 months in 24 patients (53.3%). There were 2 cases of chills and fever in the first medication; 6 patients after treatment, left ventricular ejection fraction decreased, of which 2 cases decreased by more than 10%; 19 cases of mild ST-T wave changes in the treatment process, but not Heart failure occurs. Conclusion Trastuzumab has certain effect on the cardiac function in patients with HER-2 positive breast cancer. Attention should be paid to the monitoring observation in the treatment, but the overall safety is good.